Dr. Beckermann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 21st Ave S
Nashville, TN 37232Phone+1 615-936-2000Fax+1 615-936-0605
Summary
- Dr. Kathryn Beckermann is an oncologist based in Nashville, TN, specializing in the treatment of renal cell carcinoma. She completed her Internal Medicine residency and a fellowship in Hematology and Medical Oncology at Vanderbilt University Medical Center. Dr. Beckermann is actively involved in research, as demonstrated by multiple peer-reviewed publications including in esteemed journals like The Oncologist, Lancet, and Nature Reviews Clinical Oncology. Her research mainly revolves around advanced kidney cancer therapies.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2017- Vanderbilt University Medical CenterResidency, Internal Medicine, 2012 - 2014
Vanderbilt University School of MedicineClass of 2012
Certifications & Licensure
TN State Medical License 2014 - 2026
AL State Medical License 2020 - 2020- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1563 citationsFatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysisDaniel Y. Wang, Joe-Elie Salem, Justine V. Cohen, Sunandana Chandra, Christian Menzer
JAMA Oncology. 2018-12-01 - 440 citationsAssociation of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multic...Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess, Carmen Mak, Daniel Y. Wang
The Lancet. Oncology. 2018-03-01 - 158 citationsSingle-cell protein activity analysis identifies recurrence-associated renal tumor macrophagesAleksandar Obradovic, Nivedita Chowdhury, Scott M. Haake, Casey Ager, Vinson Wang
Cell. 2021-05-27
Press Mentions
- Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell CarcinomaMarch 8th, 2021
Optimizing Benefit and Limiting Immune-Related Adverse Effects Following Checkpoint Inhibitor BlockadeJuly 3rd, 2018
May 16th, 2018 Young Lung Cancer Investigators Awarded $200K to Improve Lung Cancer OutcomesMay 16th, 2018- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
